Abstract
Introduction

54
Genome-wide association studies (GWASs) have emerged as a powerful unbiased tool to 55 identify single nucleotide polymorphisms (SNPs) associated with incidence of a particular 56 phenotype or disease [1] . Interestingly, only a small fraction of GWAS lead variants lie within 57 coding sequence and thus directly implicate a causal gene at a locus. The vast majority of 58 implicated SNPs fall in noncoding sequence, including introns and gene deserts, suggesting they 59 may play a regulatory role in gene expression. Moreover, most of these SNPs are not themselves 60 causal but exist in linkage disequilibrium (LD) with the true functional variants. The causal gene 61 driving an association signal is often not immediately apparent, unless the locus harbors a gene 62 with a known connection to the phenotype of interest. Although reports of GWASs typically 63 label each associated SNP with the name of the nearest annotated gene or most plausible 64 biological candidate at that locus, experiments in biological models are often necessary to 65 identify the true causal gene at the locus [2] [3] [4] . variant. An eQTL is a genomic region that influences gene expression either in cis or trans; 88 however, GWAS-implicated variants are predominantly believed to function in cis-acting 89 manner. Importantly, eQTL studies have identified differentially regulated transcripts hundreds 90 of kilobases away from the genotyped variant, implicating long-range chromatin looping 91 interactions in the mechanisms of some eQTLs [5, 6 ]. These differentially regulated genes then 92 become candidates for experimental manipulation (for example, through overexpression and 93 knockout of the orthologous genes in murine models) to ascertain their relevance to the 94 phenotype of interest [2] . However, identifying the causal variants underlying eQTLs through 95 functional studies is more challenging due to the poor conservation of noncoding DNA across 96 species. 97
98
Further insight into eQTL mechanisms can be gleaned by integrating risk-associated variants 99 with annotated maps of regulatory elements, such as DNase I hypersensitivity sites, chromatin 100 immunoprecipitation sequencing (ChIP-seq) peaks, and histone modifications. Candidate SNPs 101 that fall in transcriptionally active regions can then be prioritized for functional investigation. 102
Experimental approaches such as reporter assays, electrophoretic mobility shift assays (EMSA), 103
and ChIP can be employed to investigate allele-specific regulatory activity at each variant, as 104 well as determinants of differential transcription factor binding and function [7] [8] [9] to, more recently, transcription activator-like effector nucleases (TALENs) and clustered 120 regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated 9 (Cas9) 121 systems-have opened up unprecedented avenues by which to rigorously assess the functional 122 impact of novel genetic variants [12] . All three of these genome-editing tools can be used to 123 introduce targeted alterations into mammalian cells and model organisms. However, CRISPR-124
Cas9 offers an optimal combination of high targeting efficiency, ease of use, and scalability [13] . 125
The most widely used CRISPR-Cas9 system employs the Streptococcus pyogenes Cas9 nuclease, 126 which complexes with a synthetic guide RNA (gRNA) encoding a site-specific 20-nt protospacer 127 sequence that hybridizes an N 20 NGG target DNA sequence. Once Cas9 induces a double-strand 128 break three nucleotides upstream of the NGG sequence, or protospacer adjacent motif (PAM), 129 the cell employs error-prone non-homologous end joining (NHEJ) to repair the break, often 130 leading to the introduction of an insertion or deletion that may disrupt gene function. To address this issue, we performed an MPRA experiment to rapidly profile the regulatory 155 activity of 1,837 variants linked to the 16 eQTL lead SNPs identified for subcutaneous fat and/or 156 omental fat (S1 Table; see Supplementary Tables 9 and 10 in ref. 2 for more information on  157 eQTLs) and thus prioritize potentially causal candidate SNPs. We used a pool of reporter 158 constructs in which every plausible regulatory variant (i.e., all SNPs with r 2 ≥ 0.5 relative to the 159 8 16 eQTL lead SNPs) was embedded within a 144-bp genomic "tile" in six versions-major or 160 minor allele in the center, towards the 5' end (right-shifted), or towards the 3' end (left-shifted). 161
Each fragment was coupled to a reporter gene with a unique barcode identifier in the 3' 162 untranslated region. To minimize barcode-and amplification-associated biases, each fragment 163 was coupled to ~22 distinct barcodes. The pool was transfected into cultured mouse 3T3-L1 164 adipocytes or pre-adipocytes, and the copy number of each barcode was determined by RNAseq 165 and normalized to the amount of corresponding reporter DNA plasmid that entered the cells [10] . 166
From the MPRA data (S2 Table) , we prioritized variants that displayed significant allele-specific 167 enhancer activity, as measured by reporter expression, in 3T3-L1 adipocytes. We selected the 168 two variants with the strongest evidence, rs2277862 and rs10889356, for further investigation 169 (Fig 1A) . (Fig 1C) . When the 210 minor allele (A) was present, almost all signal disappeared. Of note, there was one downstream 211 nucleotide that showed a very strong signal regardless of allelic variation at rs10889356, 212
suggesting it contributes to transcriptional regulation in a manner independent of the SNP. These 213 data suggest that, for both rs2277862 and rs10889356, complexes of factors that are in part 214 anchored at the site of the SNP are responsible for modulation of local gene expression. 215
216
Genome editing of the rs2277862 site in human pluripotent stem cells 217
218
The MPRA data from 3T3-L1 adipocytes indicate that the minor allele (T) of rs2277862 (minor 219 allele frequency in Europeans = 0.15) increases transcriptional activity relative to the major allele 220 (C) (Fig 1) . This would suggest that the minor allele functions as an enhancer, the major allele 221 functions as a repressor, or both. The rs2277862 locus harbors a number of genes with no prior 222 connection to lipid metabolism, although only three-CEP250, CPNE1 and ERGIC3-show 223 evidence of differential regulation in human liver, subcutaneous fat, and omental fat biopsies. 224
The biology and relevant sites of action of all three of these genes are poorly understood. 225
Interestingly, rs2277862 is located over 50 kb away from two of these eQTL genes, CEP250 and 226 CPNE1, suggesting that it may function as a long-range enhancer or repressor (Fig 2A) . 
-test). 240 241
To define the contribution of each allele to gene expression, we sought to alter the putative 242 regulatory element encompassing rs2277862 in two hPSC lines with different genotypes at this 243 SNP: HUES 8 (C/C, major/major) and H7 (T/T, minor/minor). Although the precise regulatory 244 elements at this locus remain to be determined, the saturation mutagenesis MPRA data for the 245 site suggests that rs2277862 lies directly within such an element. We began by attempting to 246 knock in the minor allele of rs2277862 (T) onto the HUES 8 (C/C) background via HDR. Using 247 CRISPR-Cas9 with a single gRNA with a predicted cleavage site 3 bp upstream from the SNP 248 along with a 67-nt ssODN in HUES 8 cells, we obtained a single recombinant heterozygote at a 249 frequency of 0.15% (1 out of 672 clones screened) (Fig 2B) . 250
251
Because rs2277862 has an eQTL in three developmentally distinct tissues-liver, subcutaneous 252 fat, and omental fat-we reasoned that it may function as a global, non-cell-type-restricted 253 regulator of gene expression and thus modulate transcription in undifferentiated hPSCs as well. 254
We analyzed gene expression and observed no difference in CEP250, CPNE1, or ERGIC3 255 expression between wild-type clones (C/C) and the recombinant heterozygote clone (C/T) (n = 2 256 wild-type clones and 1 knock-in clone; 6 wells per clone) (Fig 2C) . We then differentiated the 257 three clones into adipocytes, the cell type in which the MPRA was originally performed. We 258 reasoned that differentiated adipocytes might have greater transcriptional activity at the 259 rs2277862 locus, perhaps by recruitment of additional transcriptional machinery to the site, and 260 thereby exhibit more pronounced gene expression differences. However, hPSC-derived knock-in 261 adipocytes (n = 2 wild-type clones and 1 knock-in clone; 6 wells per clone) demonstrated altered 262 expression of only one of the 20q11 genes, CPNE1 (down 6.9%) (Fig 2D) . of the two wild-type clones. However, when the same clones were differentiated to adipocytes, 271 the two wild-type clones displayed fairly distinct "setpoints" in gene expression, presumably due 272 to variations in differentiation efficiency. Thus, this variability between genetically equivalent 273 clones within a group could be confounding the ability to discern true differences secondary to a 274 genetic modification. 275
276
In light of the inefficiency of the HDR knock-in at the rs2277862 locus, we adopted an 277 alternative approach. Reasoning that small deletions encompassing the site of the SNP should 278 have effects on gene expression, since transcription factor binding sites are typically 8-10 279 nucleotides long, we used CRISPR-Cas9 to generate numerous deletion mutants. One 280 disadvantage of using NHEJ to introduce indels at a genomic site with a single gRNA is that a 281 wide variety of insertions and deletions are generated, and different indels may have different 282 effects on transcriptional regulatory activity. We therefore utilized a different strategy with two 283 gRNAs with cleavage sites flanking the SNP, 38 bp apart. Through this multiplexing NHEJ 284 approach we efficiently generated small deletions encompassing the candidate SNP at a 285 frequency of 59% (168 out of 285 clones screened) (Fig 3A) . The use of dual gRNAs facilitated 286 efficient generation of many hPSC clones harboring predictable, and often homozygous, 287 deletions. Due to the efficacy of the multiplexing strategy, we were easily able to generate a 288 large number of homozygous deletion ("knockout") cell clones in both the HUES 8 (C/C) and 289 (Fig 3B) . Homozygous disruption of the minor allele 307 in H7 cells (n = 8 wild-type and 6 knockout clones, 3 wells per clone) subtly decreased 308 expression of CEP250 (down 8.8%) and ERGIC3 (down 10.2%) (Fig 3C) . 309
310
In combination, the data from genome editing of the rs2277862 site in hPSCs suggest that the 311 major allele of rs2277862 functions as a transcriptional enhancer in hPSCs, and the minor allele 312 may have minimal enhancer activity as well. Intriguingly, these data are at odds with the MPRA 313 data, which suggest that the minor allele increases transcriptional activity relative to the major 314 allele. Nonetheless, the MPRA and genome-editing data agree that rs2277862 is a causal variant 315 with respect to transcriptional regulation. 316 317 Genome editing of the rs10889356 site in human pluripotent stem cells 318 319 rs10889356 is tightly linked to rs2131925 (r 2 = 0.90), the lead SNP for TG, TC and LDL-C at 320 the 1p31 locus, and possession of the minor allele at rs2131925 (MAF = 0.32) is associated with 321 a 4.9 mg/dL decrease in TG [2] . rs10889356 is situated in the promoter of the DOCK7 gene, 322 which encodes a guanine nucleotide exchange factor that has not previously been implicated in 323 lipid metabolism. ANGPTL3, the probable causal gene at this locus, lies within an intron of 324 DOCK7 and encodes a liver-specific secreted protein that inhibits endothelial lipase and 325 lipoprotein lipase, thereby increasing circulating levels of TG and HDL-C (Fig 4A) [14] . The MPRA data indicate that the major allele (G) of rs10889356 has enhancer activity relative to 342 the minor allele (A). Using dual gRNAs, we efficiently generated homozygous deletion mutants 343 for rs10889356 in H7 cells, which are homozygous major (G/G) at this SNP. We observed some 344 heterogeneity in deletion size, presumably because one of the gRNAs did not always induce a 345 DSB exactly at the predicted location 3 bp upstream from the PAM (Fig 4B) . For gene 346 expression studies, we utilized hPSC clones harboring a range of 36-to 39-bp homozygous 347 deletions as we were not able to obtain a sizeable number of deletion mutants of one particular 348 genotype. In undifferentiated hPSCs (n = 12 wild-type and 8 knockout clones, 3 wells per clone), 349 disruption of the major allele diminished expression of DOCK7 (down 8.3%), suggesting that the 350 major allele indeed confers enhancer activity (Fig 4C) . ANGPTL3 expression was too low to be 351 reliably measured in undifferentiated hPSCs, consistent with its being a liver-specific gene. 352
353
We then differentiated a subset of clones (n = 4 wild-type and 4 knockout clones, 6 wells per 354 clone) to hepatocyte-like cells (HLCs). The HLCs were characterized by expression of the liver-355 specific markers ALB and SERPINA1, and the average levels of both these transcripts were 356 roughly equivalent between wild-type and knockout clones. Expression of DOCK7 was 357 decreased in knockout HLCs, while expression of the liver-specific gene ANGPTL3 was 358 increased (Fig 4D) . However, these differences did not achieve statistical significance due to 359 marked variation in differentiation efficiency, not only among clones but also among different 360 wells from the same clone. Indeed, while average ALB expression levels were equivalent 361 between groups, the dynamic range of ALB expression within each group exceeded an order of 362 magnitude (data not shown), highlighting the tremendous variability of the HLC differentiation 363 protocol, paralleling our findings with the adipocyte differentiation protocol used in studying the 364 rs2277862 heterozygous knock-in clone. with the dCas9 and gRNA constructs, either singly or in combination. With at least two of the 379 gRNAs, expression of CEP250 and CPNE1 were diminished relative to control cells, which 380 received the dCas9 construct without an accompanying gRNA (Fig 5B) , suggesting that 381 dCas9/gRNA complexes had obstructed binding or function of a transcriptional enhancer at this 382 site. This result is directionally consistent with the data from the isogenic HUES 8 rs2277862 383 deletion mutants, which also indicated that the major allele (C) has enhancer activity, though at 384 odds with the MPRA data that suggested the minor allele (T) has enhancer activity. We validated rs10889356 as a causal variant with CRISPRi constructs targeting the rs10889356 399 site in HepG2 cultured hepatoma cells, which are homozygous major (G/G) at this SNP (Fig  400   5C ). We chose HepG2 cells so that we could assess not just DOCK7 but also ANGPTL3, the 401 latter being liver-specific. In light of the low transfection efficiency of HepG2 cells, positive 402 transfectants were isolated by fluorescence-activated cell sorting (FACS) prior to gene 403 expression analysis. With three different gRNAs, singly or in combination, expression of 404 DOCK7 was significantly decreased and expression of ANGPTL3 was significantly increased 405 relative to control cells, which received the dCas9 construct without an accompanying gRNA 406 (Fig 5D) . These results are directionally consistent with the data from the isogenic H7 HLC 407 rs10889356 deletion mutant experiment, which was also performed on a homozygous major 408 background. Additionally, both experiments recapitulated the inverse relationship between 409 DOCK7 and ANGPTL3 expression levels revealed by the human eQTL data for the locus lead 410 SNP rs2131925 [2] . 411 412
Interrogation of an rs2277862 knock-in mouse 413
414
Because independent hPSC clones displayed variable propensities for directed differentiation, 415 thereby introducing confounding variability in gene expression studies, we sought an alternative 416 approach to faithfully model the effect of regulatory variation in primary tissues of interest, 417 namely liver and fat. The noncoding region encompassing rs2277862 is well conserved in mouse 418 (Fig 6A) . Remarkably, the orthologous nucleotide in mouse also displays naturally occurring 419 variation and has been previously cataloged as rs27324996 on chromosome 2, with the same two 420 alleles (C and T) as in humans. As documented in dbSNP, rs27324996 has a MAF of 43% based 421 on genotyping analyses of 14 different inbred strains of mice. All three human eQTL genes have 422 a murine ortholog at this locus, and the orientation of these genes relative to the putative 423 regulatory variant is conserved between mouse and human (Fig 6A) . additional nucleotide changes that served to both "humanize" the sequence (i.e., make a perfect 455 match to the orthologous human sequence) and prevent re-cleavage of the knock-in allele by 456 CRISPR-Cas9. Out of 37 founder mice, there was one mouse bearing the knock-in allele (Fig  457   6B) . We bred this mouse through two generations to obtain homozygous minor allele knock-in 458 mice. 459
460
We compared Cep250, Cpne1, and Ergic3 gene expression in primary liver, subcutaneous fat, 461 and omental fat from wild-type (C/C) and homozygous knock-in (T/T) C57BL/6J littermates (n 462 = 18 wild-type and 10 knock-in mice). In liver, there was significantly decreased expression of 463 Cep250 (down 28.2%), Cpne1 (down 37.2%) and Ergic3 (down 34.1%) in the homozygous 464 knock-in mice (Fig 6C) . Notably, these changes are quite concordant with the directionality and 465 magnitudes of the changes observed between wild-type (C/C) and homozygous knockout hPSCs 466 (compare with Fig 3B) . In fat tissues from knock-in mice, no statistically significant differences 467 were apparent, due to a large degree of variance in the gene expression measurements (Fig 6C) . 468
Although no conclusions can be drawn from the fat data, the liver data from the knock-in mice in 469 combination with the genome-edited hPSC data and the CRISPRi data suggest that the site of 470 rs2277862/rs27324996 has transcriptional regulatory activity in both human and mouse. One of the principal challenges of the post-GWAS era has been cataloging the allelic spectrum 475 of causal variants underlying complex trait susceptibility. In this work, we describe a 476 methodological framework for causal variant discovery that involves high-throughput 477 identification of putative disease-causal loci through a functional reporter-based screen, MPRA, 478 followed by validation of prioritized variants in genome-edited cellular models. As a proof-of-479 concept, we focused our experimental efforts on validating two top-ranked MPRA variants that 480 are potentially causal for lipid phenotypes. 481
482
We sought to rigorously demonstrate causality for rs2277862 and rs10889356 through the 483 generation of isogenic wild-type and mutant hPSCs. Consistent with prior studies, we found the 484 generation of knock-in clones via HDR to be very inefficient compared to the generation of 485 clones with defined deletions via multiplexed NHEJ. The difference in efficiency proved to be 486 crucial to the relative success of the alternative study designs. We were only able to generate a 487 single rs2277862 heterozygous knock-in clone despite screening hundreds of clones. We found 488 that clone-to-clone variability was sufficiently high to swamp out the expected small differences 489 in gene expression-on the order of 10% to 20% differences, based on eQTLs from human tissue 490 studies-and, accordingly, little informative data was obtained from the knock-in hPSC clone. 491
The situation was even worse when using cells differentiated from the hPSCs, given the 492 increased clone-to-clone variability that resulted. 493
494
It was feasible to obtain more precise data only when numerous wild-type and mutant clones 495 were used in the experiments (i.e., large n), which in turn was only possible when using NHEJ to 496 generate knockout clones with high efficiency. The knockout study design proved fruitful for 497 both rs2277862 and rs10889356, with knockout clones displaying statistically significant, albeit 498 small, differences from wild-type clones. Even with the use of a multitude of clones, however, 499 differentiation of the hPSCs greatly increased the clone-to-clone variability and obscured any 500 differences between wild-type and knockout clones. 501 502 This is not to say that hPSCs are a poor platform for functional genetic studies. hPSCs offer 503 many attractive advantages over existing model systems, including genomic stability, 504 pluripotency, and renewability. However, it seems prudent to consider the estimated "signal" 505 from a putative disease-causal variant relative to the estimated "noise" from a directed 506 differentiation protocol prior to pursuing a disease-modeling experiment in hPSCs. For highly 507 penetrant variants with large effect sizes, hPSCs have been shown to yield informative insights 508 into human genetics. For example, Ding et al. were able to characterize the rare gain-of-function 509 variant E17K in the gene AKT2, which is associated with hypoglycemia, hypoinsulinemia, and 510 increased body fat secondary to dysregulated insulin signaling [17] . hPSC-derived AKT2 E17K 511 knock-in HLCs displayed significantly decreased glucose production, while hPSC-derived 512 adipocytes had increased TG content and increased glucose uptake compared to matched wild-513 type controls. Through disease modeling in hPSCs, Ding et al. unequivocally established a 514 dominant activating role for the AKT2 E17K mutation. However, GWAS-implicated common 515 variants would be expected to display much smaller effect sizes, suggesting that hPSC-derived 516 cell types may not be the ideal model system in which to investigate common genetic variation, 517 despite the touted benefits of isogenic disease modeling. 518
519
We explored two alternative model systems. The first involved CRISPR interference, a term that 520 is typically used to describe the repression of transcription via the positioning of dCas9 to a gene 521 promoter or coding sequence to block transcriptional initiation or elongation via steric 522 interference [15]; alternatively, dCas9 can be attached to a repressor domain such as Krüppel 523 associated box (KRAB) to effect transcriptional silencing via epigenetic chromatin modification 524
[18]. We opted to use the unadorned dCas9 protein rather than attaching an extra domain, since 525 the regulatory elements in the vicinity of the two SNPs are undefined and it was unclear whether 526 each SNP allele acted as an enhancer or repressor or was neutral. Instead, we relied on steric 527 interference to reverse any effect of the SNP allele. For both rs2277862 and rs10889356, 528
CRISPRi yielded results that were concordant with the effects observed in knockout hPSCs and 529 differentiated cells-decreased gene expression vis-à-vis the major allele of rs2277862, and 530 decreased DOCK7 and increased ANGPTL3 expression vis-à-vis the major allele of rs10889356. 531
532
Of note, we performed the CRISPRi experiments in cultured human transformed cells rather than 533 hPSCs, making the experiments far easier to perform and, in the case of HepG2 cells, allowing 534 us to use cells with inherent hepatocyte properties without having to undertake the differentiation 535 of hPSCs into HLCs. Indeed, our findings suggest that CRISPRi may be better suited to the high-536 throughput interrogation of candidate causal variants (whether nominated by MPRA or another 537 technique) than genome editing of cells, although the latter should be regarded as the gold 538 standard, especially when it entails the knock-in of a specific allelic variant. Furthermore, a 539 limitation of CRISPRi is that it relies on the major allele of a SNP having enhancer or repressor 540 activity (rather than being neutral), since it may not always be possible to identify commonly 541 used human cultured transformed cell lines with minor alleles. 542
543
The second alternative model system we attempted to use was a knock-in mouse. This is not a 544 generalizable strategy, as it depends on the human SNP sequence and the orthologous sequence 545 in the mouse genome being very closely matched, which is not often the case with noncoding 546 regions. (One possible means to overcome this limitation would be the introduction of the 547 entirety of the orthologous human locus into the mouse genome, via bacterial artificial 548 chromosome transgenesis or another approach.) Fortuitously, the human rs2277862 sequence 549 matches closely with mouse, to the extent that the mouse genome has a perfectly corresponding 550 SNP, rs27324996. This allowed us to generate a "humanized" minor allele homozygous mouse 551 to compare with the wild-type major allele homozygous mouse. The theoretical advantage of this 552 study design is that it allows for the analysis of authentic primary tissues such as liver and fat 553 without the need for directed differentiation in vitro or reliance on transformed cell lines. In 554 practice, while we observed statistically significant trends in mouse liver that were concordant 555 with our findings in genome-edited hPSCs, we found that there was substantial mouse-to-mouse 556 variability with respect to gene expression of Cep250, Cpne1, and Ergic3 in fat. Thus, the 557 challenges inherent in studying common DNA variants with small effect sizes may apply to both 558 mice and hPSC models. One difference between the model systems, of course, is that it would be 559 much easier to generate a very large number of isogenic mice, through breeding, than it would be 560 generate a very large number of independent isogenic hPSC clones in order to increase the power 561 of a study. 562 563 Finally, we note the discordance among some of the results obtained from the MPRA 564 experiments and the genome editing/CRISPRi experiments. While the results for rs10889356 565 were concordant-all three types of experiments agreed that the major allele (G) has enhancer 566 activity-with respect to rs2277862, the MPRA data suggest that the minor allele (T) has more 567 enhancer activity on a closely linked reporter gene, while the genome editing/CRISPRi data 568 suggest that the major allele (C) has more enhancer activity on a more distant endogenous gene. Addgene plasmid #48240), a dual expression construct that expresses dCas9-VP160 and sgRNA 624 from separate promoters, was modified by PCR-based methods to remove the VP160 domain 625 and include a viral 2A sequence and GFP after dCas9. Additionally, the gRNA sequence was 626 modified to include a 5-bp hairpin extension, which improves Cas9-gRNA interaction, and a 627 single base pair substitution (A-U flip) that removes a putative Pol III terminator sequence, as 628 described previously [19] . To induce embryoid body formation, wild-type and mutant hPSCs were pre-treated overnight 691 with 2% DMSO; dissociated into small clumps with Accutase; resuspended in growth medium 692 containing DMEM, 10% knockout serum replacement (Life Technologies), 2 mM GlutaMAX 693 (Life Technologies), 1% non-essential amino acids, 1% penicillin/streptomycin, and 0.1 mM 694 beta-mercaptoethanol; and transferred to low-attachment 6-well plates (Costar Ultra Low 695 Attachment; Corning Life Sciences). After one week in culture, embryoid bodies were collected 696 and replated onto gelatin-coated plates in MPC medium containing DMEM, 10% FBS, 1% 697 penicillin/streptomycin, and 2.5 ng/mL bFGF (Aldevron). Cells were serially passaged at a 1:3 698 ratio to obtain a homogenous population of MPCs by passage 3-4. 699 
